» Articles » PMID: 31057731

Polybasic Peptide-levofloxacin Conjugates Potentiate Fluoroquinolones and Other Classes of Antibiotics Against Multidrug-resistant Gram-negative Bacteria

Overview
Journal Medchemcomm
Specialty Chemistry
Date 2019 May 7
PMID 31057731
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

To address the rising threat of multidrug-resistant (MDR) bacteria, new therapeutic strategies must be developed. Efficacious drug combinations consisting of existing antibiotics and enhancer biomolecules called adjuvants offers a viable strategy. We have previously reported antibiotic hybrids consisting of tobramycin appended to different fluoroquinolones that possess potential as stand-alone antimicrobials as well as adjuvants. Herein, we report the synthesis of polybasic peptide-levofloxacin conjugates based on these tobramycin-fluoroquinolone hybrids. It was found that conjugating polybasic peptides to the fluoroquinolone levofloxacin, along with the addition of an aliphatic hydrocarbon tether, resulted in the ability of these compounds to potentiate fluoroquinolones and other antibiotics against MDR Gram-negative bacteria. The conjugates were able to potentiate ciprofloxacin, levofloxacin and moxifloxacin against MDR clinical isolates of , , and to a lesser extent, . Preliminary data revealed that the conjugates interfered with active efflux of fluoroquinolones in In addition, synergy was observed with a wide array of other antibiotics against , including those that suffered from restricted outer membrane penetration, suggesting that in addition to blocking active efflux, the polybasic peptide-levofloxacin conjugates possessed the ability to disrupt and permeabilize the outer membrane of Gram-negative bacteria.

Citing Articles

Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.

Saxena D, Maitra R, Bormon R, Czekanska M, Meiers J, Titz A NPJ Antimicrob Resist. 2025; 1(1):17.

PMID: 39843585 PMC: 11721184. DOI: 10.1038/s44259-023-00016-1.


New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.

Scoffone V, Barbieri G, Irudal S, Trespidi G, Buroni S Antibiotics (Basel). 2024; 13(1).

PMID: 38247630 PMC: 10812592. DOI: 10.3390/antibiotics13010071.


Complementary Activities of Host Defence Peptides and Antibiotics in Combating Antimicrobial Resistant Bacteria.

Lennard P, Hiemstra P, Nibbering P Antibiotics (Basel). 2023; 12(10).

PMID: 37887219 PMC: 10604037. DOI: 10.3390/antibiotics12101518.


Synthesis of Azuleno[2,1-]quinolones and Quinolines via Brønsted Acid-Catalyzed Cyclization of 2-Arylaminoazulenes.

Shoji T, Takeuchi M, Uda M, Ariga Y, Yamazaki A, Sekiguchi R Molecules. 2023; 28(15).

PMID: 37570755 PMC: 10420867. DOI: 10.3390/molecules28155785.


Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.

Jie A, Hussein M, Rao G, Li J, Velkov T Pathogens. 2022; 11(12).

PMID: 36558754 PMC: 9781023. DOI: 10.3390/pathogens11121420.


References
1.
Domalaon R, Brizuela M, Eisner B, Findlay B, Zhanel G, Schweizer F . Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria. Amino Acids. 2018; 51(3):383-393. DOI: 10.1007/s00726-018-2673-9. View

2.
Domalaon R, Sanchak Y, Koskei L, Lyu Y, Zhanel G, Arthur G . Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018; 62(4). PMC: 5914005. DOI: 10.1128/AAC.02374-17. View

3.
Domalaon R, Berry L, Tays Q, Zhanel G, Schweizer F . Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component. Bioorg Chem. 2018; 80:639-648. DOI: 10.1016/j.bioorg.2018.07.018. View

4.
Zhanel G, Decorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F . Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother. 2008; 52(4):1430-7. PMC: 2292546. DOI: 10.1128/AAC.01538-07. View

5.
Domalaon R, Idowu T, Zhanel G, Schweizer F . Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?. Clin Microbiol Rev. 2018; 31(2). PMC: 5967690. DOI: 10.1128/CMR.00077-17. View